Malaria

The Global Fund’s New Funding Model (NFM) was approved by its Board more than a year ago, representing what the Fund’s Director Mark Dybul called “a new beginning” to “achieve greater impact in the lives of people affected by HIV and AIDS, TB and malaria.

There was bad news in research published yesterday in the New England Journal of Medicine about the effectiveness of what had seemed to be the best prospect for a malaria vaccine, known by the unsexy name of 'RTS,S'. The study of the phase III trials finds that in babies (aged 6-12 weeks) the vac...